Biogen: LEQEMBI IQLIK Autoinjector Available In U.S. For Early Alzheimer's
(RTTNews) - Eisai Co. (4523.T, EII.SG) and Biogen (BIIB) announced that once weekly lecanemab-irmb subcutaneous injection - LEQEMBI IQLIK - is now available in the U.S. for initiation therapy for early Alzheimer's disease in adults with mild cognitive impairment or mild dementia
(RTTNews) - Eisai Co. (4523.T, EII.SG) and Biogen (BIIB) announced that once weekly lecanemab-irmb subcutaneous injection - LEQEMBI IQLIK - is now available in the U.S. for initiation therapy for early Alzheimer's disease in adults with mild cognitive impairment or mild dementia
BELLINGS Intelligence Score: 7
Why it matters
The availability of a new autoinjector for early Alzheimer's by Biogen is a routine product launch in the pharmaceutical sector with limited direct relevance to credit markets or systemic finance professionals.
Sources
Nasdaq
Biogen: LEQEMBI IQLIK Autoinjector Available In U.S. For Early Alzheimer's
(RTTNews) - Eisai Co. (4523.T, EII.SG) and Biogen (BIIB) announced that once weekly lecanemab-irmb subcutaneous injection - LEQEMBI IQLIK - is now available in the U.S. for initiation therapy for early Alzheimer's disease in adults with mild cognitive impairment or mild dementia